Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$70.07+0.85 (+1.23%)
Close on Nov 17, 2026Market cap $7.57BP/E 166.8Yield –
Corcept Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Corcept Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $109.70M, down 39.9% year over year. For fiscal 2025 it was $142.00M, down 28.4% from the year before. Over ten years it grew 46.4% a year on average. The highest annual figure on record is $198.30M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.00M | -28.4% |
| FY2024 | Dec 31, 2024 | $198.30M | +56.5% |
| FY2023 | Dec 31, 2023 | $126.68M | +5.3% |
| FY2022 | Dec 31, 2022 | $120.32M | -28.3% |
| FY2021 | Dec 31, 2021 | $167.89M | +10.5% |
| FY2020 | Dec 31, 2020 | $151.97M | +11.6% |
| FY2019 | Dec 31, 2019 | $136.12M | +17.7% |
| FY2018 | Dec 31, 2018 | $115.67M | +89.8% |
| FY2017 | Dec 31, 2017 | $60.94M | +231.3% |
| FY2016 | Dec 31, 2016 | $18.39M | +487.6% |
| FY2015 | Dec 31, 2015 | $3.13M | – |
| FY2014 | Dec 31, 2014 | -$27.38M | – |
| FY2013 | Dec 31, 2013 | -$37.06M | – |
| FY2012 | Dec 31, 2012 | -$36.02M | – |
| FY2011 | Dec 31, 2011 | -$27.40M | – |
| FY2010 | Dec 31, 2010 | -$22.29M | – |
| FY2009 | Dec 31, 2009 | -$17.97M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.54M | -24.3% |
| Q1 FY2026 | Mar 31, 2026 | -$16.77M | -451.6% |
| Q4 FY2025 | Dec 31, 2025 | $38.45M | -36.0% |
| Q3 FY2025 | Sep 30, 2025 | $54.48M | -25.7% |
| Q2 FY2025 | Jun 30, 2025 | $44.30M | +7.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.77M | -79.9% |
| Q4 FY2024 | Dec 31, 2024 | $60.06M | +986.2% |
| Q3 FY2024 | Sep 30, 2024 | $73.29M | +38.5% |
| Q2 FY2024 | Jun 30, 2024 | $41.19M | -2.6% |
| Q1 FY2024 | Mar 31, 2024 | $23.76M | -8.5% |
| Q4 FY2023 | Dec 31, 2023 | $5.53M | -83.4% |
| Q3 FY2023 | Sep 30, 2023 | $52.91M | +57.2% |
| Q2 FY2023 | Jun 30, 2023 | $42.29M | +134.4% |
| Q1 FY2023 | Mar 31, 2023 | $25.96M | -26.4% |
| Q4 FY2022 | Dec 31, 2022 | $33.39M | -32.4% |
| Q3 FY2022 | Sep 30, 2022 | $33.65M | -30.9% |
| Q2 FY2022 | Jun 30, 2022 | $18.04M | -59.3% |
| Q1 FY2022 | Mar 31, 2022 | $35.25M | +38.6% |
| Q4 FY2021 | Dec 31, 2021 | $49.43M | +40.9% |
| Q3 FY2021 | Sep 30, 2021 | $48.70M | +60.0% |
| Q2 FY2021 | Jun 30, 2021 | $44.34M | -16.6% |
| Q1 FY2021 | Mar 31, 2021 | $25.42M | -23.6% |
| Q4 FY2020 | Dec 31, 2020 | $35.07M | -27.6% |
| Q3 FY2020 | Sep 30, 2020 | $30.44M | -20.8% |
| Q2 FY2020 | Jun 30, 2020 | $53.19M | +108.1% |
| Q1 FY2020 | Mar 31, 2020 | $33.27M | +40.5% |
| Q4 FY2019 | Dec 31, 2019 | $48.45M | +125.2% |
| Q3 FY2019 | Sep 30, 2019 | $38.43M | -13.7% |
| Q2 FY2019 | Jun 30, 2019 | $25.56M | +68.0% |
| Q1 FY2019 | Mar 31, 2019 | $23.68M | -31.2% |
| Q4 FY2018 | Dec 31, 2018 | $21.52M | -13.5% |
| Q3 FY2018 | Sep 30, 2018 | $44.51M | +307.4% |
| Q2 FY2018 | Jun 30, 2018 | $15.21M | -2.3% |
| Q1 FY2018 | Mar 31, 2018 | $34.43M | +260.1% |
| Q4 FY2017 | Dec 31, 2017 | $24.88M | +444.6% |
| Q3 FY2017 | Sep 30, 2017 | $10.93M | +22.3% |
| Q2 FY2017 | Jun 30, 2017 | $15.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.57M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.94M | – |
See a number that looks wrong?